Expression of glucose transporters and hexokinase II in cholangiocellular carcinoma compared using [18F]-2-fluro-2-deoxy-D-glucose positron emission tomography

Cancer Science

Volumn 99, Issue 2, 2008, Pages 260-266

  Paudyal, Bishnuhari ^a   Oriuchi, Noboru ^a   Paudyal, Pramila ^a   Higuchi, Tetsuya ^a   Nakajima, Takashi ^a   Endo, Keigo ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 3; GLUCOSE TRANSPORTER 4; GLUCOSE TRANSPORTER 5; HEXOKINASE; HEXOKINASE ISOENZYME; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MULTIVARIATE ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGRESSION ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; HEXOKINASE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 38949116279     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00683.x     Document Type: Article

References (32)

1. Abdel-Nabi H, Doerr RJ, Lamonica DM et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998; 206: 755-60.
2. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung and colorectal carcinoma. J Nucl Med 2003; 44: 224-39.
3. Findlay M, Young H, Cunningham D et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumor response to fluorouracil. J Clin Oncol 1996; 14: 700-8.
4. Kim TS, Moon WK, Lee DS et al. Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer. World J Surg 2001; 25: 829-34.
5. Oriuchi N, Higuchi T, Ishikita T et al. Present role and future prospects of positron emission tomography in clinical oncology. Cancer Sci 2006; 97: 1291-7.
6. Brown RS, Leung JY, Kison PV, Zasadny KR, Flint A, Wahl RL. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med 1999; 40: 556-65.
7. Haberkorn U, Ziegler SI, Oberdorfer F et al. FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models. Nucl Med Biol 1994; 21: 827-34.
8. Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997; 80: 1046-51.
9. Higashi T, Tamaki N, Honda T et al. Expression of glucose transporter in human pancreatic tumor compared with increases FDG accumulation in PET study. J Nucl Med 1997; 38: 1337-44.
10. Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 1993; 72: 2979-85.
11. 18F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med 2002; 43: 173-80.
12. Godoy A, Ulloa V, Rodriguez F et al. Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J Cell Physiol 2006; 207: 614-27.
13. Cantuaria G, Fagotti A, Ferrandina G et al. GLUT-1 expression in ovarian carcinoma: Association with survival and response to chemotherapy. Cancer 2001; 92: 1144-50.
14. Kato H, Takita J, Miyazaki T et al. Glut-1 glucose transporter expression in esophageal squamous cell carcinoma is associated with tumor aggressiveness. Anticancer Res 2002; 22: 2635-9.
15. Petrowsky H, Wildbrett P, Husarik DB et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol 2006; 45: 43-50.
16. Anderson CD, Rice MH, Pinson CW, Chapman WC, Chari RS, Delbeke D. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 2004; 8: 90-7.
17. Roh MS, Jeong JS, Kim YH, Kim MC, Hong SH. Diagnostic utility of Glut.1 in the differential diagnosis of liver carcinomas. Hepatogastroenterology 2004; 51: 1315-18.
18. Zimmerman RL, Fogt F, Burke M, Murakata LA. Assessment of Glut-1 expression in cholangiocarcinoma, benign biliary lesions and hepatocellular carcinoma. Oncol Rep 2002; 9: 689-92.
19. Torizuka T, Zasadny KR, Recker B, Wahl RL. Untreated primary lung and breast cancers: Correlation between F-18 FDG kinetic rate constants and findings of in vitro studies. Radiology 1998; 207: 767-74.
20. Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res 1996; 56: 1164-7.
21. Yamamoto T, Seino Y, Fukumoto H et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun 1990; 170: 223-30.
22. Aloj L, Caraco C, Jagoda E, Eckelman WC, Neumann RD. Glut-1 and hexokinase expression. relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Res 1999; 15: 4709-14.
23. Sobin LH, Wittekind C, eds. TNM: Classification of Malignant Tumors, 6th edn. New York: Wiley, 2002.
24. 18F]-fluro-2-dexoy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986; 27: 235-8.
25. Lee JD, Yang WI, Park YN et al. Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased 18 F-FDG uptake. J Nucl Med 2005; 46: 1753-9.
26. Aoki D, Kawakami H, Nozawa S, Udagawa Y, Iizuka R, Hirano H. Difference in lectin binding pattern of normal human endometrium between proliferative and secretary phase. Histochemistry 1989; 92: 177-84.
27. Kunkel M, Reichert TE, Benz P et al. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 2003; 97: 1015-24.
28. Kato H, Miyazaki T, Nakajima M, Fukuchi M, Manda R, Kuwano H. Value of positron emission tomography in the diagnosis of recurrent esophageal carcinoma. Br J Surg 2004; 91: 1004-9.
29. 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg 2004; 28: 247-53.
30. Brown RS, Fisher SJ, Wahl RL. Autoradiographic evaluation of the intra-tumoral distribution of 2-deoxy-D-glucose and monoclonal antibodies in xenografts of human ovarian adenocarcinoma. J Nucl Med 1993; 34: 75-82.
31. Calvo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 1995; 36: 1625-32.
32. Shetty M, Loeb JN, Vikstrom K, Ismail-Beigi F. Rapid activation of GLUT-1 glucose transporter following inhibition of oxidative phosphorylation in clone 9 cells. J Biol Chem 1993; 268: 17.225-32.